bluebird bio submits BLA for single-dose gene therapy to treat beta-thalassemia
Bluebirdbio hi-res stock photography and images - Alamy
Cambridge gene therapy firm bluebird bio to move to Somerville - Boston Business Journal
ICER says bluebird bio's $2.1m gene therapy is cost-effective | pharmaphorum
Articles with bluebird bio
bluebird bio: One Of My Top Picks For 2021 (NASDAQ:BLUE) | Seeking Alpha
Bluebird Bio Says Cash Crunch Raises 'Going Concern' Risk - Bloomberg
bluebird bio (@bluebirdbio) / Twitter
Bluebird Bio CEO defends $1.8 million price tag for new gene therapy
bluebird bio | Pioneering Gene Therapies | Recode for Life
bluebird bio: Potential For 3 Gene Therapy Approvals (NASDAQ:BLUE) | Seeking Alpha
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics? | The Motley Fool
Bluebird Bio's beta thalassemia gene therapy already under review in Europe - STAT
JPMorgan Day 3: Bluebird Bio preps for beti-cel launch
Bluebird Bio Eliminating 30% of Workforce in Restructuring
bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies - Pharmaceutical Technology
Nick Leschly, CEO of bluebird bio spinout 2seventy bio says 2023 will be a 'special year' - Boston Business Journal
bluebird bio to Present at the 37th Annual J.P. Morgan Healthcare Conference | Business Wire
Bluebird's Gene Therapy; Neurocrine-Sosei's Pact; Twist-Abveris's Deal
BlueBird Bio's 2-day reckoning is at hand - News - MM+M
bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions | Business
Somerville gene therapy firm bluebird bio nabs win with first FDA approval following split - Boston Business Journal
Why Bluebird Bio (BLUE) Stock Is Getting Hammered | Markets Insider
PharmaShots Interview: bluebird bio's Rich Colvin Shares Insights on the Skysona to Treat Early Cerebral Adrenoleukodystrophy
Bluebird Bio Reports No Evidence that LentiGlobin for Sickle Cell Causes AML
Bluebird Bio gene therapy wins first FDA approval for rare blood disorder - MedCity News
Podcast - "Chirping" on Sickle Cell: A Discussion with bluebird bio and Dr. Anjulika Chawla, M.D., FAAP | Insights | Holland & Knight
